Unicancer R&D publications

2015

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: ...

Gravis G et al., Eur Urol. 2015 Nov 21. pii: S0302-2838(15)01103-3. doi: 10.1016/j.eururo.2015.11.005.

2015

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant ...

Ladoire S et al., Autophagy. 2015 Oct 3;11(10):1878-90. doi: 10.1080/15548627.2015.1082022.

2015

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal ...

Forbes JF,. Lancet. 2015 Dec 11. pii: S0140-6736(15)01129-0. doi: 10.1016/S0140-6736(15)01129-0.

2015

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from ...

Guiu S et al., Future Oncol. 2015;11(16):2283-97. doi: 10.2217/fon.15.102.

2015

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after ...

Gonçalves A et al. Ann Oncol. 2015 Aug;26(8):1692-7. doi: 10.1093/annonc/mdv216. Epub 2015 May 5